327 related articles for article (PubMed ID: 19657672)
1. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
[TBL] [Abstract][Full Text] [Related]
2. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
Xu J; Shetty PB; Feng W; Chenault C; Bast RC; Issa JP; Hilsenbeck SG; Yu Y
BMC Cancer; 2012 Jun; 12():243. PubMed ID: 22695491
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of RARβ2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma.
Miladi-Abdennadher I; Abdelmaksoud-Damak R; Ayadi L; Khabir A; Frikha F; Kallel L; Amouri A; Frikha M; Sellami-Boudawara T; Gargouri A; Mokdad-Gargouri R
Tumour Biol; 2010 Oct; 31(5):503-11. PubMed ID: 20571967
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
[TBL] [Abstract][Full Text] [Related]
5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
6. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.
Feng W; Orlandi R; Zhao N; Carcangiu ML; Tagliabue E; Xu J; Bast RC; Yu Y
BMC Cancer; 2010 Jul; 10():378. PubMed ID: 20642860
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.
Sharma G; Mirza S; Yang YH; Parshad R; Hazrah P; Datta Gupta S; Ralhan R
Cell Oncol; 2009; 31(6):487-500. PubMed ID: 19940364
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.
Fendri A; Masmoudi A; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Ghorbel A; Gargouri A; Mokdad-Gargouri R
Cancer Biol Ther; 2009 Mar; 8(5):444-51. PubMed ID: 19221469
[TBL] [Abstract][Full Text] [Related]
11. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
13. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
15. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
Krassenstein R; Sauter E; Dulaimi E; Battagli C; Ehya H; Klein-Szanto A; Cairns P
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):28-32. PubMed ID: 14734448
[TBL] [Abstract][Full Text] [Related]
16. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
[TBL] [Abstract][Full Text] [Related]
17. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
18. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.
Jing F; Yuping W; Yong C; Jie L; Jun L; Xuanbing T; Lihua H
Tumour Biol; 2010 Aug; 31(4):321-31. PubMed ID: 20490964
[TBL] [Abstract][Full Text] [Related]
19. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.
Van der Auwera I; Bovie C; Svensson C; Limame R; Trinh XB; van Dam P; Van Laere SJ; Van Marck E; Vermeulen PB; Dirix LY
Cancer Biol Ther; 2009 Dec; 8(23):2252-9. PubMed ID: 19829046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
